MarketCap
Facebook
X
TelegramQuarterly report 2025-Q1
added 05-14-2025
OptiNose Book Value 2011-2026 | OPTN
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value OptiNose
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -86.6 M | -56.6 M | -21.8 M | 6.79 M | 61.6 M | 119 M | 154 M | -3.84 M | -27.1 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 154 M | -86.6 M | 16.2 M |
Quarterly Book Value OptiNose
| 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -61.4 M | -40.4 M | -41.1 M | -42.9 M | -99.2 M | -86.6 M | -77.6 M | -69.7 M | -73.8 M | -56.6 M | -73.4 M | -60.8 M | -44.9 M | -21.8 M | -51.5 M | -37.1 M | -16.7 M | 6.79 M | 6.79 M | 6.79 M | 6.79 M | 61.6 M | 61.6 M | 61.6 M | 61.6 M | 119 M | 119 M | 119 M | 119 M | 154 M | 154 M | 154 M | 154 M | 17 M | 17 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 154 M | -99.2 M | 12.7 M |
Book Value of other stocks in the Drug manufacturers industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Cumberland Pharmaceuticals
CPIX
|
24.5 M | $ 5.47 | 11.18 % | $ 81.3 M |  USA |
 |
Evoke Pharma
EVOK
|
7.04 M | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
1.86 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
AcelRx Pharmaceuticals
ACRX
|
17 M | - | 7.5 % | $ 6.35 M | USA |
 |
DURECT Corporation
DRRX
|
18.3 M | - | - | $ 50.1 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-651 K | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-17.3 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
-16.3 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
46.2 M | - | - | $ 142 M | USA |
 |
Cronos Group
CRON
|
1.14 B | $ 2.63 | -4.01 % | $ 1.01 B |  Canada |
 |
Harrow Health
HROW
|
52.1 M | $ 31.21 | 1.13 % | $ 1.15 B | USA |
 |
Athenex
ATNX
|
-24.2 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
73.8 M | - | - | $ 2.06 B |  France |
 |
Catalent
CTLT
|
3.6 B | - | - | $ 11.5 B | USA |
 |
HEXO Corp.
HEXO
|
314 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Eagle Pharmaceuticals
EGRX
|
234 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
5.14 B | - | - | $ 28.9 M |  Irlanda |
 |
Organogenesis Holdings
ORGO
|
434 M | $ 2.41 | -6.95 % | $ 305 M | USA |
 |
Bausch Health Companies
BHC
|
-82 M | $ 5.42 | -0.55 % | $ 1.98 B | Canada |
 |
Pacira BioSciences
PCRX
|
778 M | $ 22.64 | -3.78 % | $ 1.05 B | USA |
 |
Solid Biosciences
SLDB
|
180 M | $ 6.92 | -9.31 % | $ 606 M | USA |
 |
Canopy Growth Corporation
CGC
|
487 M | $ 1.04 | -2.8 % | $ 112 M | Canada |
 |
Tilray
TLRY
|
3.33 B | $ 5.32 | -3.27 % | $ 3.29 B | Canada |
 |
Aurora Cannabis
ACB
|
609 M | $ 3.32 | -0.9 % | $ 182 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
4.41 M | $ 1.09 | -7.63 % | $ 1.35 M | USA |
 |
Jupiter Wellness
JUPW
|
35 M | - | - | $ 33.6 M | USA |
 |
Lannett Company
LCI
|
-251 M | - | 1.15 % | $ 7.11 M | USA |
 |
OrganiGram Holdings
OGI
|
306 M | $ 1.07 | -1.83 % | $ 102 M | Canada |
 |
Evolus
EOLS
|
-23.1 M | $ 6.5 | -1.22 % | $ 419 M | USA |
 |
Sundial Growers
SNDL
|
1.1 B | $ 1.43 | -2.05 % | $ 3.37 M | Canada |
 |
Veru
VERU
|
18.3 M | $ 2.11 | 0.96 % | $ 30.9 M | USA |
 |
Emergent BioSolutions
EBS
|
649 M | $ 7.94 | -3.29 % | $ 407 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
265 M | - | - | $ 193 M | Canada |
 |
ProPhase Labs
PRPH
|
63.6 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
-252 M | - | - | $ 1.42 B | USA |
 |
cbdMD
YCBD
|
7.23 M | $ 0.77 | -6.44 % | $ 3.1 M | USA |
 |
Assertio Holdings
ASRT
|
94 M | $ 23.32 | - | $ 149 M | USA |
 |
PetIQ
PETQ
|
868 M | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
86.5 M | $ 6.9 | -7.01 % | $ 272 M | USA |
 |
Recro Pharma
REPH
|
58.7 M | - | -4.76 % | $ 65.3 M | USA |
 |
SCYNEXIS
SCYX
|
49.4 M | $ 0.74 | -4.0 % | $ 37 M | USA |
 |
PLx Pharma
PLXP
|
51.7 M | - | -27.8 % | $ 2.56 M | USA |
 |
Viatris
VTRS
|
14.7 B | $ 16.48 | -4.52 % | $ 19.2 B | USA |
 |
Zomedica Corp.
ZOM
|
115 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
46.2 M | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
37 M | $ 0.79 | -0.55 % | $ 28.4 M | USA |
 |
Tricida
TCDA
|
218 K | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
22.7 M | $ 1.04 | -16.13 % | $ 4.46 M |  China |
 |
TherapeuticsMD
TXMD
|
26.9 M | $ 2.0 | 0.5 % | $ 23.1 M | USA |